Skip to main content
SpringerLink
Log in

Effects of Levosimendan on Quality of Life and Emotional Stress in Advanced Heart Failure Patients

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Aim

Levosimendan improves central hemodynamics and symptoms in acutely decompensated chronic heart failure (CHF) patients. However, its effects on quality of life, emotional stress and functional capacity of patients with advanced CHF have not been properly investigated.

Methods and results

Sixty-three advanced CHF patients (NYHA III-IV, LVEF<30%) were randomized (2:1) to receive either a 24-h levosimendan infusion of 0.1 μg/kg/min or placebo. Questionnaires addressing quality of life [Kansas City Cardiomyopathy Questionnaire (KCCQ), functional and overall, Duke’s Activity Status Index (DASI)] and emotional stress [Zung self-rating depression scale (SDS), Beck Depression Inventory (BDI)], as well as plasma BNP and 6-min walking distance (6MWT as a marker of exercise capacity) were assessed before treatment and at hospital discharge. A significant improvement in NYHA class (2.1 ± 0.7 from 3.3 ± 0.7, p < 0.01), 6 MWT (305 ± 152 from 215 ± 142 m, p < 0.01) and plasma BNP (598 ± 398 from 1,078 ± 756 pg/ml, p < 0.01) was observed post-treatment only in levosimendan-treated group. KCCQ functional (45 ± 19 from 35 ± 17%, p < 0.05) and overall (34 ± 13 from 28 ± 11%, p < 0.05), DASI (26 ± 13 from 22 ± 12, p < 0.05), Zung SDS (38 ± 12 from 42 ± 13, p < 0.01) and BDI (11 ± 6 from 14 ± 8, p < 0.05) scores also improved in levosimendan-treated patients, while remained unchanged in the placebo group. The hospital length stay was shorter in levosimendan group compared to placebo (3.2 ± 1.7 versus 5.8 ± 2.1 days, p < 0.01). Levosimendan-induced BNP reduction was significantly correlated with concomitant increase in 6MWT (r = 0.643, p < 0.001) as well as with the decrease of BDI (r = 0.30, p < 0.05) and Zung SDS (r = 0.25, p = 0.05).

Conclusion

Levosimendan seems to have a beneficial effect on quality of life, physical activity and emotional stress in advanced CHF patients, reducing concurrently hospitalization length.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. McBride BF, White MC. Levosimendan: implications for clinicians. J Clin Pharmacol 2003;43:1071–81.

    Article  PubMed  CAS  Google Scholar 

  2. Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs 2003;63:2651–71.

    Article  PubMed  CAS  Google Scholar 

  3. Kass DA, Solaro J. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation 2006;113:305–15.

    Article  PubMed  Google Scholar 

  4. Parissis JT, Filippatos G, Farmakis D, Adamopoulos S, Paraskevaidis I, Kremastinos D. Levosimendan for the treatment of acute heart failure syndromes. Expert Opin Pharmacother 2005;6:2741–51.

    Article  PubMed  CAS  Google Scholar 

  5. Jamali IN, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Intra-coronary levosimendan enhances contractile function of stunned myocardium. Anesth Analg 1997;85:23–9.

    Article  PubMed  CAS  Google Scholar 

  6. Slawsky MT, Colucci WS, Gottlieb SS, Greenberg BH, Haeusslein E, Hare J, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000;102:2222–7.

    PubMed  CAS  Google Scholar 

  7. Nieminem M, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903–12.

    Article  Google Scholar 

  8. Follath F, Cleland JGF, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomized double-blind trial. Lancet 2002;360:196–202.

    Article  PubMed  CAS  Google Scholar 

  9. Maisel AS, Krshnawamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Breathing not properly multinational study investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161–7.

    Article  PubMed  CAS  Google Scholar 

  10. Beck AT, Steer RA, Garbin MG. Psychometric properties of Beck Depression Inventory: twenty-five years of evaluation. Clin Psychol Rev 1988;8:77–100.

    Article  Google Scholar 

  11. Zung WWK, Richards CB, Short MJ. Self-rating depression scale in an outpatient clinic. Arch Gen Psychiatry 1965;13:508–15.

    PubMed  CAS  Google Scholar 

  12. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245–55.

    Article  PubMed  CAS  Google Scholar 

  13. Hlatky M, Boineau R, Higginbotham M, Lee KL, Mark DB, Califf RM, et al. A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol 1989;15:651–4.

    Article  Google Scholar 

  14. Packer M, Colucci WS, Fisher L. Development of a comprehensive new end-point for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study. J Card Fail 2003;9:S61.

    Article  Google Scholar 

  15. Parissis J, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005;96:423–6.

    Article  PubMed  CAS  Google Scholar 

  16. Tachinaba H, Cheng HJ, Ukai T, Igawa A, Zhang Z-S, Little WC, et al. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol 2005;288:H914–22.

    Article  Google Scholar 

  17. Parissis J, Adamopoulos S, Antoniades C, Kostakis G, Rigas A, Kyrzopoulos S, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004;93:1309–12.

    Article  PubMed  CAS  Google Scholar 

  18. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS, et al. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol 2006;47:752–6.

    Article  PubMed  Google Scholar 

  19. Havranek EP, Ware M, Lowes BD. Prevalence of depression in patients with congestive heart failure. Am J Cardiol 1999;84:348–50.

    Article  PubMed  CAS  Google Scholar 

  20. Joynt KE, Whellan DJ, O’ Connor CM. Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. J Card Fail 2004;10:258–70.

    Article  PubMed  Google Scholar 

  21. Jiang W, Alexander J, Christopher E, Kuchibhatla M, Gaulden LH, Cuffe MS, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001;161:1849–56.

    Article  PubMed  CAS  Google Scholar 

  22. Adamopoulos S, Parissis J, Kremastinos D. A glossary of circulating cytokines in chronic heart failure. Eur J Heart Fail 2001;3:517–26.

    Article  PubMed  CAS  Google Scholar 

  23. Pasic J, Levy WC, Sullivan MD. Cytokines in depression and heart failure. Psychosom Med 2003;65:181–93.

    Article  PubMed  Google Scholar 

  24. Parissis J, Adamopoulos S, Rigas A, Kostakis G, Karatzas D, Venetsanou K, et al. Comparison of circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with chronic heart failure with versus without symptoms of depression. Am J Cardiol 2004;94:1326–8.

    Article  PubMed  CAS  Google Scholar 

  25. Ferketich A, Ferguson JP, Binkley PF. Depressive symptoms and inflammation among heart failure patients. Am Heart J 2005;150:132–6.

    Article  PubMed  Google Scholar 

  26. Maytin M, Colucci W. Cardioprotection: a new paradigm in the acute management of acute heat failure syndromes. Am J Cardiol 2005;96:26G–31G.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Author notes

  1. John T. Parissis

    Present address: , Aftokratoros Irakliou 17, 15122, Maroussi, Athens, Greece

Authors and Affiliations

  1. Second Cardiology Department and Heart Failure Unit, University of Athens Medical School, Attikon University Hospital, Athens, Greece

    John T. Parissis, Constantinos Papadopoulos, Maria Nikolaou, Vassiliki Bistola, Dimitrios Farmakis, Ioannis Paraskevaidis, Gerasimos Filippatos & Dimitrios Kremastinos

Authors
  1. John T. Parissis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Constantinos Papadopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Nikolaou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vassiliki Bistola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dimitrios Farmakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ioannis Paraskevaidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gerasimos Filippatos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Dimitrios Kremastinos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John T. Parissis.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parissis, J.T., Papadopoulos, C., Nikolaou, M. et al. Effects of Levosimendan on Quality of Life and Emotional Stress in Advanced Heart Failure Patients. Cardiovasc Drugs Ther 21, 263–268 (2007). https://doi.org/10.1007/s10557-007-6034-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-007-6034-2

Key words

Search

Navigation